Fundraising Fox

Dyne Therapeutics

NASDAQ: DYN

Waltham, US · Founded 2017 · Delaware corporation · 5 known investors

dyne-tx.com ↗

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.

BiotechMedical Devicesin /dynetx@dyne_tx

Founders & leadership

LK
Lawrence Klein, Ph.D.Director
RS
Richard ScalzoExecutive Officer
JB
Joshua BrummExecutive Officer, Director
DL
David LubnerDirector
EH
Edward HurwitzDirector
DK
Dirk KerstenDirector
JM
Jonathan McNeill, M.D.Executive Officer
CS
Catherine Stehman-Breen, M.D.Director
OBOxana Beskrovnaya, Ph.D.
Oxana Beskrovnaya, Ph.D.Executive Officer
RS
Romesh Subramanian, Ph.D.Executive Officer
JR
Jason RhodesDirector

Investors · 5

Atlas VentureCambridge · $500K – $1M
MPM BioImpactBoston · $1M – $15M
MPM Capital
Vida VenturesLos Angeles
ForbionreportedNaardenvia Dirk Kersten · board

Reported raises · per SEC filings

Form D private placements
▶$115.7MraisedAug 2020 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence Klein, Ph.D.Director
  • Richard ScalzoExecutive Officer
  • Joshua BrummExecutive Officer, Director
  • David LubnerDirector
  • Edward HurwitzDirector
  • Dirk KerstenDirector
  • Jonathan McNeill, M.D.Executive Officer
  • Catherine Stehman-Breen, M.D.Director
  • Jason RhodesDirector
  • Oxana Beskrovnaya, Ph.D.Executive Officer
  • Romesh Subramanian, Ph.D.Executive Officer
Offering amount
$115.7M
Amount sold
$115.7M
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news